These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 15071285

  • 61. Nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants.
    Ashkenazi-Hoffnung L, Dotan M, Livni G, Amir J, Bilavsky E.
    Am J Infect Control; 2014 Sep; 42(9):991-5. PubMed ID: 25179332
    [Abstract] [Full Text] [Related]

  • 62. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
    Resch B, Egger B, Kurath-Koller S, Urlesberger B.
    Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
    [Abstract] [Full Text] [Related]

  • 63. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab.
    Chan P, Li A, Paes B, Abraha H, Mitchell I, Lanctôt KL, CARESS investigators.
    Pediatr Infect Dis J; 2015 Dec; 34(12):e290-7. PubMed ID: 26780032
    [Abstract] [Full Text] [Related]

  • 64. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
    Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S.
    Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
    [Abstract] [Full Text] [Related]

  • 65. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
    Oncel MY, Mutlu B, Kavurt S, Baş AY, Demirel N, Akyol M, Erdeve O, Dilmen U.
    Turk J Pediatr; 2012 Feb; 54(4):344-51. PubMed ID: 23692714
    [Abstract] [Full Text] [Related]

  • 66. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants.
    Yoshihara S, Kusuda S, Mochizuki H, Okada K, Nishima S, Simões EA, C-CREW Investigators.
    Pediatrics; 2013 Nov; 132(5):811-8. PubMed ID: 24127479
    [Abstract] [Full Text] [Related]

  • 67. Use of palivizumab in Germany: data from 2002-2007.
    Simon A, Nowak H, Sterz R.
    Klin Padiatr; 2011 Sep; 223(5):292-8. PubMed ID: 21509705
    [Abstract] [Full Text] [Related]

  • 68. Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab.
    Meissner HC, Rennels MB, Pickering LK, Hall CB.
    Pediatr Infect Dis J; 2004 Mar; 23(3):284-5. PubMed ID: 15014320
    [No Abstract] [Full Text] [Related]

  • 69. Association Between Updated Guideline-Based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections.
    Grindeland CJ, Mauriello CT, Leedahl DD, Richter LM, Meyer AC.
    Pediatr Infect Dis J; 2016 Jul; 35(7):728-32. PubMed ID: 27078122
    [Abstract] [Full Text] [Related]

  • 70. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM.
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [Abstract] [Full Text] [Related]

  • 71. Palivizumab administration in preterm infants in France: EPIPAGE-2 cohort study.
    Torchin H, Rousseau J, Marchand-Martin L, Truffert P, Jarreau PH, Ancel PY.
    Arch Pediatr; 2018 Feb; 25(2):89-94. PubMed ID: 29395887
    [Abstract] [Full Text] [Related]

  • 72. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
    Sanchez-Luna M, Burgos-Pol R, Oyagüez I, Figueras-Aloy J, Sánchez-Solís M, Martinón-Torres F, Carbonell-Estrany X.
    BMC Infect Dis; 2017 Oct 17; 17(1):687. PubMed ID: 29041909
    [Abstract] [Full Text] [Related]

  • 73. Evaluation of compliance with palivizumab recommendations in a multicenter study of young children presenting to the emergency department with bronchiolitis.
    Mansbach J, Kunz S, Acholonu U, Clark S, Camargo CA.
    Pediatr Emerg Care; 2007 Jun 17; 23(6):362-7. PubMed ID: 17572518
    [Abstract] [Full Text] [Related]

  • 74. A cost-benefit analysis of RSV prophylaxis in high-risk infants.
    Schrand LM, Elliott JM, Ross MB, Bell EF, Mutnick AH.
    Ann Pharmacother; 2001 Oct 17; 35(10):1186-93. PubMed ID: 11675842
    [Abstract] [Full Text] [Related]

  • 75. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee.
    Pediatrics; 2014 Aug 17; 134(2):415-20. PubMed ID: 25070315
    [Abstract] [Full Text] [Related]

  • 76. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
    Warren A, Langley JM, Thomas W, Scott J.
    Can J Cardiol; 2007 May 01; 23(6):463-6. PubMed ID: 17487291
    [Abstract] [Full Text] [Related]

  • 77. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
    Régnier SA.
    Vaccine; 2013 Sep 13; 31(40):4347-54. PubMed ID: 23896421
    [Abstract] [Full Text] [Related]

  • 78. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis.
    La Via WV, Notario GF, Yu XQ, Sharma S, Noertersheuser PA, Robbie GJ.
    Pulm Pharmacol Ther; 2013 Dec 13; 26(6):666-71. PubMed ID: 23523663
    [Abstract] [Full Text] [Related]

  • 79. RSV Hospitalizations in Comparison With Regional RSV Activity and Inpatient Palivizumab Administration, 2010-2013.
    Glick AF, Kjelleren S, Hofstetter AM, Subramony A.
    Hosp Pediatr; 2017 May 13; 7(5):271-278. PubMed ID: 28381595
    [Abstract] [Full Text] [Related]

  • 80. Economic results of a palivizumab seasonal prophylaxis using a cohorting software and vial sharing.
    Coletta E, Coppolino S, Federico F, Fulia F.
    Ital J Pediatr; 2010 Jul 07; 36():48. PubMed ID: 20609229
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.